Navigation Links
ERT Facilitates Global Growth with Appointment of Klaus Besier to Board of Directors
Date:12/7/2010

PHILADELPHIA, Dec. 7, 2010 /PRNewswire-FirstCall/ -- ERT (Nasdaq: ERES) a global provider of technology and services to the pharmaceutical, biotechnology and medical device industries, today announced the appointment of Klaus Besier to the Company's Board of Directors. This strategic appointment will enable ERT to draw on Mr. Besier's extensive experience and international perspective in helping companies develop, implement and execute global growth strategies to further penetrate health care and clinical markets.

Mr. Besier brings to ERT more than 30 years of executive experience in leading software technology companies. He has served as President and CEO of SAP America, Inc. and is credited with driving its growth in North and South America, Australia and New Zealand from $50 million to $1 billion in revenues in less than five years. In addition, as President and CEO of Firepond Inc., Mr. Besier took the company public in one of the most successful IPOs of 2000.

Mr. Besier also held the position of President and CEO of Neoware, Inc., where he drove significant changes in the company's go-to-market and partner strategies. The improved corporate structure led to significant growth and visibility for the organization, resulting in its acquisition by HP in 2007 with a total transaction value of more than $300 million. Most recently, Mr. Besier served as CEO of Pramata, Inc., where he refined a go-to-market strategy that is steering the company toward growth with Fortune 500 customers. Today, he is the CEO of RES Software and a member of the Board of Directors of ICG Commerce.

Joel Morganroth, Chairman and Chief Scientific Officer of ERT, comments, "ERT strives to continually improve in all areas of business and grow into adjacent and complementary markets, ensuring our pledge to our customers of 'getting it done right.' With his wealth of experience and capabilities in developing and implementing successful growth strategies, we are confident that Klaus will greatly contribute to the strategic direction of the business and help ERT achieve its many goals."  

Klaus Besier adds, "As the industry leader in cardiac safety, respiratory and multi-mode ePRO solutions for the clinical trial market, ERT has provided unparalleled scientific and regulatory leadership to the global health care industry. I am delighted to be part of a strong management team consisting of individuals who share a long industry track record. I look forward to working with them to take ERT to an even higher level of leadership and technological innovation."

For further information on ERT and its technology and services, please email info@ert.com, call +1 215 972 0420 or visit www.ert.com.

About ERT

Based in Philadelphia, PA, eResearchTechnology, Inc. (www.ert.com) is a global provider of technology and services to the pharmaceutical, biotechnology and medical device industries.  The Company is a market leader in providing centralized core-diagnostic electrocardiographic (ECG) technology and services to evaluate cardiac safety in clinical development. It is also a leading provider of centralized respiratory technology and services to evaluate pulmonary function efficacy and safety in clinical development.  Sponsors can further use the Company's solutions to streamline the clinical trials process by automating the collection, analysis, and distribution of ePRO clinical data using multi-mode technology in all phases of clinical development as well as selected medical devices for the clinical trials and healthcare industries.

Statements included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties, which could cause actual results to differ materially from those expressed or implied from such statements. These risks and uncertainties include, without limitation, the Company's ability to obtain new contracts, variability in size, scope, and duration of projects, integration of acquisitions, competitive factors, technological development, market demand, and other factors described in the Company's filings with the Securities and Exchange Commission.  The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.


'/>"/>
SOURCE ERT
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Verathon Introduces the GlideScope(R) Cobalt Advanced Video Laryngoscope (AVL); New Digital Technology Facilitates Quick Intubations
2. Oxford Finance Corporation Facilitates Entry for Reata Pharmaceuticals into Asian Markets
3. VR Charlotte Facilitates the Sale of Amramp of Charlotte
4. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
5. Dr. Roger Kenneth Hershline PhD MD, CEO of Global Humanceuticals, Inc. Donates New HIV Drug
6. Directors Forum: PEPFAR and the Global AIDS Response
7. Alfacell Corporation to Present at UBS Global Life Sciences Conference
8. Baxa Corporation Extends Global Reach With New Distribution Agreements in Colombia and the Dominican Republic
9. Global HIV Vaccine Enterprise Names Alan Bernstein as Inaugural Executive Director, Opens New Secretariat
10. President Clinton Highlights MWW Group at the 2007 Clinton Global Initiative for its Stop Neglected Tropical Disease Campaign
11. Hillary Clinton Pledges Bold Approach to Stopping HIV/AIDS & Global Poverty
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 Roche ... received 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) ... severe sepsis or septic shock. With this clearance, Roche ... provide a fully integrated solution for sepsis risk assessment ... associated with bacterial infection and PCT levels in blood ...
(Date:6/23/2016)... -- Research and Markets has announced the addition ... to their offering. The ... commercial environment for MedImmune to enter. The US ageing population ... to drive considerable growth for effective anti-influenza medications. The introduction ... considerably, but development is still in its infancy. ...
(Date:6/23/2016)... and INDIANAPOLIS , June ... receiving a Lilly Diabetes Tomorrow,s Leaders Scholarship is any ... scholarship winners, announced today online at www.diabetesscholars.org ... type 1 diabetes stand in the way of academic ... supported the Foundation,s scholarship program since 2012, and continues ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... ... industry today announced its strategic partnership with Connance, a healthcare industry leader ... two companies’ proven, proprietary technology combine to provide health systems, hospitals and ...
(Date:6/26/2016)... ... , ... Pixel Film Studios Released ProSlice Levels, a Media Slicing Effect ... a whole new perspective by using the title layers in ProSlice Levels to ... ProSlice Levels contains over 30 Different presets to choose from. FCPX users ...
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... Austin ... of the American College of Mohs Surgery and to Dr. Russell Peckham for medical ... and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery ...
(Date:6/25/2016)... ... 25, 2016 , ... Dr. Calvin Johnson has dedicated his ... implemented orthobiologic procedures as a method for treating his patients. The procedure is ... to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use to help ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is ... associated with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of ...
Breaking Medicine News(10 mins):